Remove Communication Remove Inpatient Remove Insurance Coverage and Processing
article thumbnail

ProxsysRx’s Meds To Beds Program Makes Immediate Impact Upon Launch At TMH

Proxsys Rx

In 2022 alone, TMH’s 710+ physicians, and its medical staff, saw 31,190 inpatient admissions. Even with her insurance coverage, the co-pay was beyond her means. The gentleman in question had no health insurance coverage at all, and the cash price for his prescription was far beyond his means to pay.

article thumbnail

NHC Comments on Centers for Medicare & Medicaid Services (CMS) in response to the CY 2025 OPPS proposed rule

Putting Patients First Blog

By incorporating these measures into both inpatient and outpatient quality reporting, CMS is promoting a more equitable health care system and ensuring that interventions are targeted to reduce health disparities. The NHC encourages CMS to continue this approach in the future to maintain a collaborative and informed decision-making process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ProxsysRx’s Meds To Beds Program Makes Immediate Impact Upon Launch At TMH

Proxsys Rx

In 2022 alone, TMH’s 710+ physicians, and its medical staff, saw 31,190 inpatient admissions. Even with her insurance coverage, the co-pay was beyond her means. The gentleman in question had no health insurance coverage at all, and the cash price for his prescription was far beyond his means to pay.

article thumbnail

NHC Comments on CMS 2026 Notice of Benefit and Payment Parameters

Putting Patients First Blog

General Support for CMS Proposals The NHC commends CMS for its ongoing commitment to advancing health equity, improving access to care, ensuring program integrity, and maintaining affordability through Marketplace coverage. Copay Assistance and Drug Coverage in Large Group Plans Accumulator Adjustment Programs and Cost Sharing.

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. Meanwhile, in Germany, the AMNOG process is conducted twelve months after the drug is launched, thus giving freedom to the company to set the drug’s price during this period.